Xvivo Perfusion Valuation
Is XVIVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of XVIVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XVIVO (SEK415.5) is trading below our estimate of fair value (SEK518.54)
Significantly Below Fair Value: XVIVO is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XVIVO?
Other financial metrics that can be useful for relative valuation.
| What is XVIVO's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 13.09b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.6x |
| Enterprise Value/EBITDA | 405x |
| PEG Ratio | 3.6x |
Price to Earnings Ratio vs Peers
How does XVIVO's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 89.2x | ||
VIMIAN Vimian Group | 199.2x | 58.6% | SEK 17.9b |
SUS Surgical Science Sweden | 30.7x | 27.0% | SEK 6.4b |
ARJO B Arjo | 22.4x | 20.9% | SEK 11.2b |
ELOS B Elos Medtech | 104.3x | n/a | SEK 5.7b |
XVIVO Xvivo Perfusion | 130.3x | 36.3% | SEK 13.1b |
Price-To-Earnings vs Peers: XVIVO is expensive based on its Price-To-Earnings Ratio (130.3x) compared to the peer average (89.2x).
Price to Earnings Ratio vs Industry
How does XVIVO's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: XVIVO is expensive based on its Price-To-Earnings Ratio (130.3x) compared to the European Medical Equipment industry average (30.3x).
Price to Earnings Ratio vs Fair Ratio
What is XVIVO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 130.3x |
| Fair PE Ratio | 35.4x |
Price-To-Earnings vs Fair Ratio: XVIVO is expensive based on its Price-To-Earnings Ratio (130.3x) compared to the estimated Fair Price-To-Earnings Ratio (35.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 415.50 | SEK 440.00 +5.9% | 13.9% | SEK 520.00 | SEK 340.00 | n/a | 6 |
| Jun ’25 | SEK 440.00 | SEK 408.00 -7.3% | 12.0% | SEK 468.00 | SEK 340.00 | n/a | 6 |
| May ’25 | SEK 379.00 | SEK 408.00 +7.7% | 12.0% | SEK 468.00 | SEK 340.00 | n/a | 6 |
| Apr ’25 | SEK 275.00 | SEK 382.60 +39.1% | 9.0% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Mar ’25 | SEK 280.50 | SEK 382.60 +36.4% | 9.0% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Feb ’25 | SEK 284.50 | SEK 389.60 +36.9% | 7.8% | SEK 425.00 | SEK 340.00 | n/a | 5 |
| Jan ’25 | SEK 329.50 | SEK 377.00 +14.4% | 16.3% | SEK 450.00 | SEK 280.00 | n/a | 5 |
| Dec ’24 | SEK 273.00 | SEK 363.75 +33.2% | 17.1% | SEK 450.00 | SEK 280.00 | n/a | 4 |
| Nov ’24 | SEK 231.00 | SEK 371.67 +60.9% | 18.8% | SEK 450.00 | SEK 280.00 | n/a | 3 |
| Oct ’24 | SEK 274.50 | SEK 391.67 +42.7% | 11.5% | SEK 450.00 | SEK 340.00 | n/a | 3 |
| Sep ’24 | SEK 289.50 | SEK 391.67 +35.3% | 11.5% | SEK 450.00 | SEK 340.00 | n/a | 3 |
| Aug ’24 | SEK 323.00 | SEK 376.67 +16.6% | 7.2% | SEK 405.00 | SEK 340.00 | n/a | 3 |
| Jul ’24 | SEK 303.50 | SEK 376.67 +24.1% | 7.2% | SEK 405.00 | SEK 340.00 | n/a | 3 |
| Jun ’24 | SEK 286.00 | SEK 376.67 +31.7% | 7.2% | SEK 405.00 | SEK 340.00 | SEK 440.00 | 3 |
| May ’24 | SEK 306.00 | SEK 370.00 +20.9% | 7.2% | SEK 405.00 | SEK 340.00 | SEK 379.00 | 3 |
| Apr ’24 | SEK 244.00 | SEK 354.00 +45.1% | 8.7% | SEK 385.00 | SEK 312.00 | SEK 275.00 | 3 |
| Mar ’24 | SEK 235.00 | SEK 365.50 +55.5% | 9.1% | SEK 400.00 | SEK 312.00 | SEK 280.50 | 4 |
| Feb ’24 | SEK 227.50 | SEK 365.50 +60.7% | 9.1% | SEK 400.00 | SEK 312.00 | SEK 284.50 | 4 |
| Jan ’24 | SEK 183.00 | SEK 357.50 +95.4% | 11.3% | SEK 400.00 | SEK 291.00 | SEK 329.50 | 4 |
| Dec ’23 | SEK 195.60 | SEK 357.50 +82.8% | 11.3% | SEK 400.00 | SEK 291.00 | SEK 273.00 | 4 |
| Nov ’23 | SEK 169.80 | SEK 366.60 +115.9% | 11.1% | SEK 403.00 | SEK 291.00 | SEK 231.00 | 5 |
| Oct ’23 | SEK 134.00 | SEK 375.60 +180.3% | 11.7% | SEK 408.00 | SEK 291.00 | SEK 274.50 | 5 |
| Sep ’23 | SEK 179.00 | SEK 374.40 +109.2% | 12.4% | SEK 408.00 | SEK 285.00 | SEK 289.50 | 5 |
| Aug ’23 | SEK 225.00 | SEK 374.50 +66.4% | 13.8% | SEK 408.00 | SEK 285.00 | SEK 323.00 | 4 |
| Jul ’23 | SEK 215.00 | SEK 385.75 +79.4% | 13.3% | SEK 435.00 | SEK 300.00 | SEK 303.50 | 4 |
| Jun ’23 | SEK 236.00 | SEK 385.75 +63.5% | 13.3% | SEK 435.00 | SEK 300.00 | SEK 286.00 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.